Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ro and Found are two prominent telehealth platforms offering GLP-1 medications for weight management and metabolic health. Ro uses a direct-to-consumer model with rapid provider assessment, while Found emphasizes a longer intake process and ongoing coach support. Both report significant patient adoption, reflecting growing demand for remote metabolic care.

When evaluating telehealth GLP-1 providers, the distinction between rapid assessment and comprehensive intake matters clinically. Ro prioritizes speed and accessibility; Found prioritizes multidisciplinary support. This article compares their approaches, discusses when each model may be appropriate, and explains how genetic insights can support a more informed conversation with any provider—including those at PlexusDx who work with compounded formulations.

Ro's Direct-Access Model and Clinical Workflow

Ro operates a streamlined telehealth model: you complete an online health history, consult a provider (physician or nurse practitioner), receive a prescription if approved, and obtain medication via mail. The process typically takes hours to one business day. Ro offers branded semaglutide (Wegovy) and tirzepatide (Zepbound, Mounjaro) through its platform alongside compounded alternatives in some states.

Ro's strength lies in rapid access for patients who have already researched GLP-1 therapy and want quick initiation. However, the brief clinical encounter may not capture nuanced metabolic history, family history, or contraindications. Patients with complex comorbidities or polypharmacy concerns should disclose these thoroughly during their initial consultation.

Found's Comprehensive Intake and Ongoing Support Model

Found uses a more extended onboarding: multi-step questionnaires, behavioral coaching, and registered dietitian reviews occur before medication initiation. The platform emphasizes lifestyle integration, ongoing weight tracking, and monthly check-ins. Found partners with compounded medications in most cases, allowing flexibility in dosing and formulation.

Found's model supports patients seeking structured behavioral change alongside pharmacotherapy. The longer intake and coaching framework can reduce side effects and improve adherence. However, this approach takes longer to reach medication start—typically 1–2 weeks—and requires active engagement with behavioral content. Patients preferring minimal interaction may find the model more intensive than needed.

Ro vs Found: Key Operational and Clinical Differences

The table below summarizes the operational, clinical, and commercial distinctions between Ro and Found. Both platforms use licensed providers and compliant pharmacies, but their workflows, support structures, and medication sourcing differ substantially. Your choice depends on your comfort with rapid assessment versus comprehensive intake, your preference for behavioral coaching, and your medication sourcing preferences.

Factor Ro Found
Speed to Medication Hours to 1 business day 1–2 weeks with intake and coaching
Provider Type MDs, NPs, PAs via brief consultation MDs/NPs plus registered dietitian review
Ongoing Support Limited; reactive to patient questions Structured behavioral coaching and monthly check-ins
Medication Options Branded (Wegovy, Zepbound, Mounjaro) and compounded Primarily compounded formulations
Approximate Monthly Cost $199–$349 depending on medication $149-$289/mo including coaching
Initial Questionnaire Depth Standard health history form Extended metabolic, behavioral, and dietary assessment
Contraindication Screening Provider-based during consultation Multi-step review by provider and dietitian
Dosing Flexibility Standard branded doses; some compounded options Highly customizable compounded doses

Clinical Scenarios: When Each Model May Be Appropriate

Ro's rapid-access model suits patients with straightforward health profiles, no contraindications, and confirmed GLP-1 tolerance or prior use. If you've used semaglutide before and respond well, Ro's efficiency may be valuable. Conversely, if you have diabetes, cardiovascular disease, thyroid cancer history, or take multiple medications, Found's extended intake and dietitian review provide additional safety oversight.

Found's comprehensive model is especially relevant for patients new to GLP-1 therapy, those with complex medical histories, or anyone who benefits from behavioral coaching. The dietitian review can identify potential drug-nutrient interactions and support sustainable diet modifications. Neither platform is inherently superior; the better choice depends on your medical complexity and preference for support depth.

The Role of Genetic Predisposition in GLP-1 Personalization

Both Ro and Found rely on clinical assessment to select initial GLP-1 candidates, but neither platform currently offers genetic testing to predict response. Variants in GLP1R, GIPR, FTO, and MC4R genes may influence medication efficacy and side-effect tolerance, though research is ongoing. Genetic context cannot predict exact outcomes, but it can support a more informed conversation with your provider about expected response patterns.

PlexusDx offers the Precision Peptide Genetic Test (standalone or add-on), which examines variants in peptide-pathway genes linked to GLP-1 receptor function, insulin secretion, and metabolic regulation. This test may help provide context for why a patient responds robustly to one medication versus another, or why side effects vary. The results should be interpreted with a qualified healthcare provider—they inform conversation but do not determine treatment alone.

Safety, Eligibility, and When to Seek More Intensive Screening

Both platforms screen for GLP-1 contraindications: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe pancreatitis, and severe kidney disease. Pregnant or breastfeeding individuals should not use GLP-1 medications. However, screening depth differs: Ro's brief consultation may miss nuanced risk factors, while Found's multi-step intake catches more complexity.

If you have diabetes, cardiovascular disease, gastrointestinal disorders, or take medications affecting absorption, request a comprehensive clinical review before starting. Ensure your provider understands your full medication list, family history, and any prior GLP-1 experience. Both platforms allow medical records transfer to support informed decision-making.

Medication Sourcing: Branded vs. Compounded Considerations

Ro offers both branded GLP-1 medications (Wegovy for weight loss, Ozempic for diabetes, Mounjaro for diabetes) and compounded alternatives depending on state and insurance. Found primarily uses compounded semaglutide and tirzepatide, which are chemically equivalent but manufactured by licensed 503A compounding pharmacies rather than pharmaceutical companies. Compounded options typically cost less than branded products and allow dose customization.

Branded medications undergo FDA manufacturing oversight and stability testing under defined conditions. Compounded medications are regulated by state pharmacy boards and USP standards. Both are legitimate, but patients should understand the sourcing difference. If cost or dose flexibility is paramount, compounded options through Found or PlexusDx may appeal. If you prefer pharmaceutical-grade certainty, Ro's branded offerings provide that pathway.

How PlexusDx Supports a More Personalized Approach

PlexusDx partners with licensed 503A compounding pharmacies to provide customizable semaglutide and tirzepatide at costs lower than most branded alternatives. Our model emphasizes precision and personalization: we support genetic testing to contextualize metabolic predispositions, facilitate provider consultations, and work collaboratively with your clinician to optimize dosing and formulation.

The Precision Peptide Genetic Test offered by PlexusDx examines variants in GLP1R, GIPR, FTO, and MC4R genes that relate to GLP-1 receptor expression, appetite regulation, and weight-management potential. This test provides no guarantees about medication response but may help explain individual differences in tolerance and efficacy. Results should always be interpreted with a qualified provider as part of a comprehensive treatment plan.

Whether you choose Ro's rapid model, Found's comprehensive approach, or PlexusDx's precision-wellness framework, the goal remains the same: safe, effective, personalized metabolic care. A qualified provider—whether through a telehealth platform or your primary care physician—should evaluate your full medical context, review genetic or biomarker data if available, and tailor recommendations to your individual needs and goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Ro and Found?

Ro prioritizes rapid provider access and medication delivery (hours to 1 day), while Found uses extended intake, dietitian review, and ongoing behavioral coaching (1–2 weeks start). Ro offers branded and compounded options; Found focuses mainly on compounded medications.

Is Ro or Found better for patients with complex medical histories?

Found's multidisciplinary intake and dietitian screening may be safer for complex patients. Ro works well for straightforward cases. Either way, disclose all medications, comorbidities, and family history to your provider for thorough contraindication screening.

Does genetic testing help choose between Ro or Found?

Neither platform currently offers genetic testing. However, a Precision Peptide Genetic Test from PlexusDx can provide context about your peptide-pathway predispositions and support a more informed conversation with your provider about expected response patterns and tolerability.

Are compounded GLP-1 medications as safe as branded versions?

Compounded semaglutide and tirzepatide from licensed 503A pharmacies meet USP standards and state pharmacy regulations. They are chemically equivalent to branded products but manufactured in specialized compounding facilities. Both are legitimate options; discuss sourcing preferences with your provider.

How can I decide between Ro, Found, and other providers like PlexusDx?

Consider your comfort with rapid assessment versus comprehensive intake, your need for behavioral coaching, your medication sourcing preference (branded versus compounded), and cost. A qualified provider conversation—informed by genetic insights if available—should guide your choice.

What is PlexusDx's approach to GLP-1 personalization?

PlexusDx uses licensed 503A compounding pharmacies and offers the Precision Peptide Genetic Test to support precision conversations with providers. We do not guarantee outcomes but aim to provide context for informed, individualized treatment decisions.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves